IP: Patents in Emerging Markets (Brazil, Russia, India, China)
Thursday, November 29 2012
8:00 am – 9:15 am
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA
In our rapidly evolving global economy, IP protection in countries outside the US and the jurisdiction of the EPO plays an increasingly important role. Pursuing patent protection in emerging economies, particularly in the BRIC countries (Brazil, Russia, India, China) is associated with a particular set of issues that patent counsel, together with business development managers, need take in consideration, such as different patent valuation parameters and uncertainties due evolving legal systems. Further discussion points include:
- Overall value of patent protection in emerging markets
- Differences in filing strategies
- Issues around enforceability
- Different perceptions of the value of patents as business and legal tools in various countries
- Special considerations for academic institutions and early stage companies
Our panel experts will discuss these and more topics from the perspective of the in-house IP specialist and will offer valuable insight in this rapidly growing field of IP.
- Claire Vasios, Ph.D., Vice President, Intellectual Property, Alkermes, plc.
- Beth Mathiesen, Director, Intellectual Property, Sanofi Pasteur
Dr. Vasios is the head of the Intellectual Property group for Alkermes, plc, a fully integrated global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products, a substantial clinical pipeline of product candidates, and an extensive patent portfolio. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. Dr. Vasios leads a team of five patent professionals located in the Waltham and Athlone offices. She is responsible for the company's overall IP strategy, both domestic and foreign, including driving the creation of new intellectual property, monitoring freedom-to-operate issues and developing risk mitigation strategies. Claire has a Ph.D. in Microbiology from Rutgers University/Rutgers Medical School and has worked for Alkermes for over 20 years.
Beth Mathiesen is a Director of Intellectual Property at Sanofi Pasteur, the vaccines division of Sanofi. Sanofi Pasteur provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Dr. Mathiesen works with a global IP team from the US, Canada, and France to develop the company's IP strategy, both foreign and domestic. Beth has a Ph.D. in Virology from Harvard University and a law degree from Suffolk University. Prior to Sanofi Pasteur, Beth worked at Pfizer and Finnegan, Henderson, Farabow, Garrett, & Dunner, LLP.